Skip to content

uniQure QURE EPS (Basic)

EPS (Basic) at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$1.84-17.2%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
-$0.69+11.5%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$0.03-100%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$1.28+19.0%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$1.91+54.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$0.84+4.5%

Other financials

Income statement

See full
Revenue$3.6M+127%
Gross profit$3.3M+144%
Operating income-$45.7M-16.2%
Net income-$53.5M-22.7%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$140.0M-35.6%
Total debt$63.3M-4.3%
Total equity$149.3M+343%
Total assets$778.7M+28.6%

Cash flow

See full
Operating cash flow-$38.2M+13.3%
CapEx$140.0K+11.1%
Free cash flow-$38.4M+13.2%

Valuation

See full
Market cap$3.09B+78.4%
Enterprise value$3.02B+124%
P/S170.9×+85.1×

Profitability

See full
Gross margin90.6%-2.9pp
Operating margin-1,059.7%+380pp
Net margin-1,154.4%+89.3pp
FCF margin-953.7%+169pp

Returns & leverage

See full
Return on equity-228.2%-11.6pp
Debt / equity0.4×-1.5×
Current ratio10.4×-1.6×

Where this comes from

Reported directly by uniQure in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: uniQure’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about uniQure's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is uniQure's EPS (basic)?
uniQure (QURE) reported EPS (basic) of -$0.85 in Q1 2026.
How has uniQure's EPS (basic) changed year-over-year?
uniQure's EPS (basic) decreased by 3.7% year-over-year, from -$0.82 to -$0.85.
What is the long-term trend for uniQure's EPS (basic)?
Over 4 years (2021 to 2025), uniQure's EPS (basic) has grown at a -16.7% compound annual growth rate (CAGR), from $7.15 to -$3.45.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.